CRSP Logo

Crispr Therapeutics AG (CRSP) Stock Forecast & Price Prediction

Live CRSP Stock Price & Analysis

Home โ€บ Stocks โ€บ Switzerland | NASDAQ | Healthcare | Biotechnology

$49.72

+6.23 (14.33%)

12 Month Price Forecast For CRSP

$49.72
Current Price
$4.26B
Market Cap
29 Ratings
Buy 16
Hold 12
Sell 1
Wall St Analyst Ratings

Distance to CRSP Price Forecasts

+439.0%
To High Target of $268.00
+64.9%
To Median Target of $82.00
-35.6%
To Low Target of $32.00

CRSP Price Momentum

+25.2%
1 Week Change
+23.4%
1 Month Change
-39.5%
1 Year Change
+26.3%
Year-to-Date Change
-45.4%
From 52W High of $91.10
+36.1%
From 52W Low of $36.52

๐Ÿค” Considering CRISPR (CRSP)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 16, 2025 2:20 AM UTC

CRSP Analyst Ratings & Price Targets

Based on our analysis of 35 Wall Street analysts, CRSP has a bullish consensus with a median price target of $82.00 (ranging from $32.00 to $268.00). The overall analyst rating is Buy (7.7/10). Currently trading at $49.72, the median forecast implies a 64.9% upside. This outlook is supported by 16 Buy, 12 Hold, and 1 Sell ratings.

Conversely, the most conservative target is provided by Terence Flynn at Morgan Stanley, suggesting a 35.6% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CRSP Analyst Consensus

16
Buy
12
Hold
1
Sell

CRSP Price Target Range

Low
$32.00
Average
$82.00
High
$268.00
Current: $49.72

Latest CRSP Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CRSP.

Date Firm Analyst Rating Change Price Target
Feb 14, 2025 Evercore ISI Group Liisa Bayko Outperform Upgrade $99.00
Feb 14, 2025 Morgan Stanley Terence Flynn Underweight Maintains $32.00
Feb 13, 2025 JMP Securities Silvan Tuerkcan Market Outperform Reiterates $86.00
Feb 13, 2025 Chardan Capital Geulah Livshits Buy Maintains $84.00
Feb 13, 2025 Stifel Benjamin Burnett Hold Maintains $49.00
Feb 13, 2025 HC Wainwright & Co. Mitchell Kapoor Buy Reiterates $65.00
Feb 13, 2025 Goldman Sachs Salveen Richter Neutral Maintains $57.00
Feb 12, 2025 Needham Gil Blum Buy Reiterates $84.00
Feb 12, 2025 Truist Securities Joon Lee Buy Maintains $120.00
Feb 12, 2025 Barclays Gena Wang Equal-Weight Maintains $56.00
Feb 12, 2025 RBC Capital Luca Issi Sector Perform Maintains $48.00
Feb 3, 2025 HC Wainwright & Co. Mitchell Kapoor Buy Initiates $65.00
Jan 14, 2025 Needham Gil Blum Buy Reiterates $84.00
Jan 7, 2025 B of A Securities Geoff Meacham Buy Maintains $85.00
Dec 20, 2024 JMP Securities Silvan Tuerkcan Market Outperform Reiterates $86.00
Dec 10, 2024 Chardan Capital Geulah Livshits Buy Maintains $94.00
Nov 6, 2024 RBC Capital Luca Issi Sector Perform Reiterates $53.00
Nov 6, 2024 Needham Gil Blum Buy Reiterates $84.00
Nov 6, 2024 Barclays Gena Wang Equal-Weight Maintains $55.00
Oct 4, 2024 RBC Capital Luca Issi Sector Perform Maintains $53.00

Stocks Similar to Crispr Therapeutics AG

The following stocks are similar to CRISPR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Crispr Therapeutics AG (CRSP) Financial Data

Crispr Therapeutics AG has a market capitalization of $4.26B with a P/E ratio of -11.5x. The company generates $37.31M in trailing twelve-month revenue with a -215.0% profit margin.

Revenue growth is -82.3% quarter-over-quarter, while maintaining an operating margin of -181.0% and return on equity of -19.2%.

Valuation Metrics

Market Cap $4.26B
Enterprise Value $2.58B
P/E Ratio -11.5x
PEG Ratio -9.9x
Price/Sales 114.3x

Growth & Margins

Revenue Growth (YoY) -82.3%
Gross Margin +100.0%
Operating Margin -181.0%
Net Margin -215.0%
EPS Growth -82.5%

Financial Health

Cash/Price Ratio +44.6%
Current Ratio 22.1x
Debt/Equity 11.6x
ROE -19.2%
ROA -13.0%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Crispr Therapeutics AG logo

Crispr Therapeutics AG (CRSP) Company Overview

About Crispr Therapeutics AG

What They Do

Develops gene-based medicines using CRISPR technology.

Business Model

The company focuses on creating gene-editing therapies for serious diseases using its proprietary CRISPR/Cas9 platform. It generates revenue through the development and commercialization of its therapeutic programs, which target various conditions including hemoglobinopathies and cancers, often in collaboration with strategic partners.

Additional Information

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and was incorporated in 2013. Its lead product candidate, CASGEVY, is aimed at treating transfusion-dependent beta-thalassemia and severe sickle cell disease. The company also has a diverse portfolio of investigational therapies for oncology, autoimmune diseases, and cardiovascular conditions.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

393

CEO

Dr. Samarth Kulkarni Ph.D.

Country

Switzerland

IPO Year

2016

Crispr Therapeutics AG (CRSP) Latest News & Analysis

CRSP stock latest news image
Quick Summary

CRISPR Therapeutics (CRSP) stock rose over 9% following a positive quarterly earnings report released after market hours on Tuesday.

Why It Matters

The surge in CRISPR Therapeutics' stock reflects strong investor confidence following positive quarterly earnings, indicating potential growth and profitability in the biotech sector.

Source: The Motley Fool
Market Sentiment: Positive
CRSP stock latest news image
Quick Summary

CRISPR Therapeutics anticipates significant developments in 2025, including updates on CAR T products CTX112 and CTX131, and a strong cash position of $1.9 billion as of December 31, 2024.

Why It Matters

The news highlights CRISPR Therapeutics' robust pipeline and strong financial position, indicating potential growth and innovation in gene therapies, which could drive stock performance and investor interest.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRSP stock latest news image
Quick Summary

CRSP reports positive fourth-quarter results and the successful commercial launch of its CRISPR-based gene therapy, Casgevy, is underway.

Why It Matters

Positive fourth-quarter results and a successful CRISPR therapy launch signal strong growth potential for CRSP, likely boosting investor confidence and stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
CRSP stock latest news image
Quick Summary

CRISPR Therapeutics AG reported a quarterly loss of $0.44 per share, beating estimates of a $1.15 loss, compared to earnings of $1.10 per share in the same quarter last year.

Why It Matters

CRISPR's smaller-than-expected loss indicates improving financial health, potentially boosting investor confidence and impacting stock performance positively.

Source: Zacks Investment Research
Market Sentiment: Negative
CRSP stock latest news image
Quick Summary

Investing in underperforming stocks may be beneficial if recovery prospects exist; however, many lagging companies currently lack such potential.

Why It Matters

Stocks underperforming without recovery potential can indicate poor fundamentals, increasing risk for investors. Caution is advised in selecting investments with sustainable growth prospects.

Source: The Motley Fool
Market Sentiment: Positive
CRSP stock latest news image
Quick Summary

Investors will closely watch CRSP's Q4 2024 earnings call for updates on sales of Casgevy, the company's first marketed product.

Why It Matters

Casgevy's sales performance will indicate market acceptance and revenue potential, impacting CRSP's financial outlook and investor sentiment.

Source: Zacks Investment Research
Market Sentiment: Neutral

Frequently Asked Questions About CRSP Stock

What is Crispr Therapeutics AG's (CRSP) stock forecast for 2025?

Based on our analysis of 35 Wall Street analysts, Crispr Therapeutics AG (CRSP) has a median price target of $82.00. The highest price target is $268.00 and the lowest is $32.00.

Is CRSP stock a good investment in 2025?

According to current analyst ratings, CRSP has 16 Buy ratings, 12 Hold ratings, and 1 Sell ratings. The stock is currently trading at $49.72. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CRSP stock?

Wall Street analysts predict CRSP stock could reach $82.00 in the next 12 months. This represents a 64.9% increase from the current price of $49.72. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Crispr Therapeutics AG's business model?

The company focuses on creating gene-editing therapies for serious diseases using its proprietary CRISPR/Cas9 platform. It generates revenue through the development and commercialization of its therapeutic programs, which target various conditions including hemoglobinopathies and cancers, often in collaboration with strategic partners.

What is the highest forecasted price for CRSP Crispr Therapeutics AG?

The highest price target for CRSP is $268.00 from at , which represents a 439.0% increase from the current price of $49.72.

What is the lowest forecasted price for CRSP Crispr Therapeutics AG?

The lowest price target for CRSP is $32.00 from Terence Flynn at Morgan Stanley, which represents a -35.6% decrease from the current price of $49.72.

What is the overall CRSP consensus from analysts for Crispr Therapeutics AG?

The overall analyst consensus for CRSP is bullish. Out of 35 Wall Street analysts, 16 rate it as Buy, 12 as Hold, and 1 as Sell, with a median price target of $82.00.

How accurate are CRSP stock price projections?

Stock price projections, including those for Crispr Therapeutics AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.